Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 3731579
- Development stage
- Phase 1
- Lead developer
- Boehringer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BI 3731579 is an investigational small molecule drug developed by Boehringer Ingelheim. It is currently in Phase 1 clinical trials, where it is being evaluated for its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The specific mechanism of action and therapeutic target of BI 3731579 have not been disclosed publicly as of June 2025. The drug has been administered orally in clinical studies to assess the effect of food on its pharmacokinetics and to determine the safety profile across different dosing regimens[1][2][3][4][5]. No approved indications or known adverse events have been reported.
Beyond the preview
Go deeper on BI 3731579.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 3731579.